# Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus

> **NCT02916706** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 254 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Teneligliptin 20mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02916706
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2018-08-14
- **Final completion:** —
- **Target enrollment:** 254 (ACTUAL)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02916706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02916706, "Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02916706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*